Genmab | GEN - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Almirall EUR 350.64M 52.12M 2025-12
Amarin USD 194.46M 12.23M 2025-12
Amgen USD 25.49B 3.7B 2025-12
argenx SE USD 1.04B 371.99M 2025-06
AstraZeneca USD 30.62B 3.44B 2025-12
Bayer EUR 32.58B 3.63B 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Demant DKK 7.42B 1.63B 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Fresenius Medical Care EUR 6.25B 485.68M 2025-12
Galapagos EUR 152.86M 213.7M 2025-12
Genmab DKK 1.43B 686M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
GN Store Nord DKK 7.32B 153M 2025-12
GRIFOLS EUR 2.02B 135.85M 2025-12
Hikma Pharmaceutical USD 1.45B 603M 2025-12
Insmed USD 468.87M 51.66M 2025-12
Lonza CHF 3.57B 421M 2025-12
Merck EUR 9.04B 405M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 28.35B 3.76B 2025-12
UCB EUR 4.4B 470M 2025-12